Sherry X. Yang, MD, PhD, on Recurrence Score Data From the TAILORx Breast Cancer Trial

Posted: Tuesday, April 25, 2023

Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses the clinical implications of new findings on the use of the 21-gene recurrence score system to guide decisions about adjuvant chemotherapy in women with breast cancer. For those patients with high recurrence scores, even chemotherapy did not mitigate their increased risk. (Abstract LB119)

---